Oncotelic Therapeutics (OTLC) Short Interest Ratio & Short Volume

Short interest is the volume of Oncotelic Therapeutics shares that have been sold short but have not yet been closed out or covered. As of July 31st, traders have sold 83,200 shares of OTLC short. 0.03% of Oncotelic Therapeutics' shares are currently sold short. Learn More on Oncotelic Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.03% of Oncotelic Therapeutics' floating shares are currently sold short.

Oncotelic Therapeutics saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 83,200 shares, an increase of 2,583.9% from the previous total of 3,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.03% of Oncotelic Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Oncotelic Therapeutics: Surrozen, Inc. (1.73%), IGM Biosciences, Inc. (2.56%), PMV Pharmaceuticals, Inc. (1.84%), Cabaletta Bio, Inc. (13.39%), Metagenomi, Inc. (6.38%), Genenta Science S.p.A. Unsponsored ADR (0.05%), Assertio Holdings, Inc. (5.70%), Forte Biosciences, Inc. (1.17%), Sutro Biopharma, Inc. (4.14%), MediciNova, Inc. (0.26%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), MicroStrategy Incorporated ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks.

Short selling OTLC is an investing strategy that aims to generate trading profit from Oncotelic Therapeutics as its price is falling. OTLC shares are trading up $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Oncotelic Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of OTLC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OTLC, twice per month. The most recent reporting period available is July, 31 2025.